Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Farmakokinetisk studie av Venetoclax-tabletter knust og oppløst i en løsning

27. oktober 2026 oppdatert av: Children's Hospital Medical Center, Cincinnati

En farmakokinetisk studie av Venetoclax-tabletter knust og oppløst i en løsning hos barn og unge voksne med hematologiske maligniteter

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.

Primary Objectives

• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution

Secondary Objectives

  • To evaluate the safety of crushed venetoclax tablets administered as an oral solution
  • To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
  • To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
  • To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution

Studieoversikt

Detaljert beskrivelse

Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.

Studietype

Observasjonsmessig

Registrering (Antatt)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Site Public Contact
  • Telefonnummer: (513) 636-2799
  • E-post: cancer@cchmc.org

Studiesteder

    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado
        • Hovedetterforsker:
          • Kelly Faulk, MD
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30329
        • Har ikke rekruttert ennå
        • Children's Healthcare of Atlanta - Arthur M. Blank Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Himalee Sabnis, MD, MS
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Hovedetterforsker:
          • Sarah Tasian, MD
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Texas Children's Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michelle Redell, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Children's Hospital of Wisconsin
        • Hovedetterforsker:
          • Zachary Graff, MD
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 sekund til 38 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.

Patients must be <39 years of age at time of study enrollment.

Beskrivelse

Inclusion Criteria:

  • Age: Patients must be <39 years of age at time of study enrollment
  • Diagnosis: Patients may have a diagnosis of any hematologic malignancy
  • Central access: Patients must have an existing venous or arterial access line for PK blood draws
  • Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
  • Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
  • Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.

Exclusion Criteria:

  • Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
  • Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: OTHER
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Children and Young Adults

Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care.

Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tidsramme: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tidsramme: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. november 2023

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

24. oktober 2023

Først innsendt som oppfylte QC-kriteriene

8. november 2023

Først lagt ut (Faktiske)

14. november 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere